{"id":"stanozolol","rwe":[],"tags":[{"label":"stanozolol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor","category":"target"},{"label":"ESR1","category":"gene"},{"label":"CYP2C19","category":"gene"},{"label":"CYP2C9","category":"gene"},{"label":"A14AA02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hereditary angioneurotic edema","category":"indication"},{"label":"Approved 1960s","category":"decade"},{"label":"Anabolic Agents","category":"pharmacology"},{"label":"Androgens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":194.293,"date":"","count":61,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=194)"},{"llr":93.969,"date":"","count":13,"signal":"Testicular atrophy","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=94)"},{"llr":90.661,"date":"","count":20,"signal":"Left ventricular hypertrophy","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=91)"}],"commonSideEffects":[],"contraindications":["Benign prostatic hyperplasia","Breast Carcinoma in Males","Breastfeeding (mother)","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Heart disease","Humoral hypercalcemia of malignancy","Hypercalcemia","Hypercholesterolemia","Kidney disease","Neoplasm of prostate","Nephrotic syndrome","Pregnancy, function"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=STANOZOLOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:02:07.837760+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:02:14.752439+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=STANOZOLOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:02:15.446904+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:02:15.977202+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2079587/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:02:15.889593+00:00"}},"allNames":"winstrol","offLabel":[],"synonyms":["stanozolol","androstanazol","androstanazole","androstanazolestanazol","estazol","stanazolol","tevabolin"],"timeline":[{"date":"1962-01-09","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Winstrol, also known as stanozolol, is a small molecule drug that targets the estrogen receptor. Originally developed and currently owned by Lundbeck Inc, it was FDA approved in 1962 for the treatment of hereditary angioneurotic edema. Although off-patent, there are no generic manufacturers listed. As a stanozolol drug class, it is a synthetic anabolic steroid with androgenic and anabolic effects. Key safety considerations include its potential for liver toxicity and cardiovascular side effects.","approvals":[{"date":"1962-01-09","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Winstrol","ecosystem":[{"indication":"Hereditary angioneurotic edema","otherDrugs":[{"name":"berotralstat","slug":"berotralstat","company":"Biocryst"},{"name":"ecallantide","slug":"ecallantide","company":"Dyax Corp."},{"name":"icatibant","slug":"icatibant","company":"Shire Orphan Therap"},{"name":"lanadelumab","slug":"lanadelumab","company":"Dyax Corp"}],"globalPrevalence":null}],"mechanism":{"target":"Estrogen receptor","novelty":"Follow-on","targets":[{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"}],"modality":"Small Molecule","drugClass":"stanozolol","explanation":"","oneSentence":"","technicalDetail":"Stanozolol is a non-aromatizable, 17-alpha-alkylated anabolic steroid that competitively binds to the androgen receptor, but also exhibits anti-estrogenic activity by binding to the estrogen receptor, thereby inhibiting the action of estrogen in the body."},"commercial":{"launchDate":"1962","_launchSource":"DrugCentral (FDA 1962-01-09, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2477","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=STANOZOLOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=STANOZOLOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:41:47.053259","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:17.729086+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"oxymetholone","drugSlug":"oxymetholone","fdaApproval":"1972-01-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"prasterone","drugSlug":"prasterone","fdaApproval":"","patentExpiry":"Mar 19, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oxandrolone","drugSlug":"oxandrolone","fdaApproval":"1964-07-21","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"stanozolol","indications":{"approved":[{"name":"Hereditary angioneurotic edema","source":"DrugCentral","snomedId":82966003,"regulator":"FDA"}],"offLabel":[{"name":"Antithrombin III deficiency","source":"DrugCentral","drugName":"STANOZOLOL"},{"name":"Aplastic anemia","source":"DrugCentral","drugName":"STANOZOLOL","evidenceCount":42,"evidenceLevel":"moderate"},{"name":"Fibrinogen Excess","source":"DrugCentral","drugName":"STANOZOLOL","evidenceCount":1,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Lundbeck Inc","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"oxymetholone","brandName":"oxymetholone","genericName":"oxymetholone","approvalYear":"1972","relationship":"same-class"},{"drugId":"prasterone","brandName":"prasterone","genericName":"prasterone","approvalYear":"","relationship":"same-class"},{"drugId":"oxandrolone","brandName":"oxandrolone","genericName":"oxandrolone","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05024877","phase":"PHASE2,PHASE3","title":"Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":["MDS"],"enrollment":50,"completionDate":"2023-12-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146591","MMSL":"5510","NDDF":"001252","UNII":"4R1VB9P8V3","VUID":"4018261","CHEBI":"CHEBI:9249","VANDF":"4018261","INN_ID":"958","RXNORM":"10032","UMLSCUI":"C0038149","chemblId":"CHEMBL2079587","ChEMBL_ID":"CHEMBL2079587","KEGG_DRUG":"D00444","DRUGBANK_ID":"DB06718","PUBCHEM_CID":"25249","SNOMEDCT_US":"126103004","IUPHAR_LIGAND_ID":"10369","MESH_DESCRIPTOR_UI":"D013197"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Lundbeck Inc","relationship":"Current Owner"}],"publicationCount":598,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A14AA02","allCodes":["A14AA02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Lundbeck Inc","companyId":"","modality":"Small molecule","firstApprovalDate":"1962","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1962-01-09T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:17.729086+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}